Welcome to our dedicated page for C4 Therapeutics SEC filings (Ticker: CCCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
Lynx1 Capital Management LP and Weston Nichols report a 7.3% beneficial stake in C4 Therapeutics, Inc. common stock, totaling 7,098,133 shares. This percentage is based on 96,914,418 shares outstanding as of October 29, 2025, from the company’s Form 10‑Q for the quarter ended September 30, 2025.
The shares are directly held by Lynx1 Master Fund LP, which has the right to receive dividends and sale proceeds, while Lynx1 Capital Management LP serves as investment manager and Weston Nichols is its control person. The reporting parties certify the holdings were not acquired to change or influence control of C4 Therapeutics.
C4 Therapeutics, Inc. shareholder update: a group of Soleus investment entities filed an amended Schedule 13G/A reporting passive ownership of C4 Therapeutics common stock.
Soleus Capital Management, L.P., Soleus GP, LLC and Guy Levy each report beneficial ownership of 10,334,114 shares, representing 9.99% of the outstanding common stock based on 96,914,418 shares as of October 29, 2025. This total includes warrants to purchase up to 6,530,172 shares, subject to beneficial ownership limitations in those warrants. Other Soleus entities, including Soleus Private Equity Fund III, L.P., report 6,072,822 shares, or 5.9% of the class, including warrants to purchase up to 5,822,829 shares.
The filing states the securities were not acquired and are not held for the purpose of changing or influencing control of C4 Therapeutics, and multiple Soleus entities and Guy Levy disclaim beneficial ownership beyond Section 13(d) reporting obligations.
Morgan Stanley and Morgan Stanley & Co. LLC report a significant passive stake in C4 Therapeutics, Inc. common stock. They beneficially own 8,974,191 shares, representing 9.3% of the class as of 12/31/2025, with all voting and dispositive power held on a shared basis.
The firms state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of C4 Therapeutics.
C4 Therapeutics Chief Medical Officer Leonard Reyno reported an open-market sale of company stock. On January 16, 2026, he sold 10,000 shares of C4 Therapeutics, Inc. common stock at a price of $2.22 per share, as shown by transaction code "S" for a disposition. After this trade, he directly beneficially owns 156,382 shares of the company’s common stock.
C4 Therapeutics, Inc. filed a Form 8-K to furnish information about a new corporate update. On January 14, 2026, the company issued a press release that outlines its milestones through 2028 and highlights recent achievements, and has attached this press release as Exhibit 99.1.
The disclosure is made under Item 7.01 (Regulation FD Disclosure), which means the information in the press release and Item 7.01 is being furnished rather than filed and is not subject to certain liability provisions of the Exchange Act or automatically incorporated into other securities law filings. The report is signed on behalf of the company by its Chief Financial Officer and Treasurer, Kendra R. Adams.
C4 Therapeutics, Inc. is filing a shelf registration statement to offer up to $400,000,000 of common stock, preferred stock, debt securities, warrants and units. This includes a sales agreement prospectus for up to $125,000,000 of common stock that may be issued from time to time through TD Securities (USA) LLC under an at-the-market program, which is part of the $400,000,000 total.
The company is a clinical-stage biopharmaceutical developer focused on targeted protein degradation, led by its cemsidomide program in multiple myeloma and non-Hodgkin lymphoma, where Phase 1 data have shown generally well-tolerated profiles and anti-tumor activity. In an October 2025 underwritten offering, C4 Therapeutics raised approximately $117.0 million in net proceeds and structured additional potential proceeds through pre-funded and other warrants. The shelf registration is intended to provide flexible access to capital for general corporate purposes, including research and development and pipeline expansion.
C4 Therapeutics (CCCC) filed its Q3 2025 10‑Q, reporting collaboration revenue of $11.23 million and a net loss of $32.17 million. Revenue declined year over year as milestone and services mix shifted, while expenses rose on a $10.73 million non‑cash impairment tied to a new sublease, bringing total operating expenses to $45.64 million. Interest and other income contributed $2.25 million.
Cash, cash equivalents and marketable securities were $199.8 million as of September 30, 2025. The company sold 2,950,225 shares via its at‑the‑market program for $7.5 million in net proceeds and later terminated the ATM sales agreement. Shares outstanding were 74,174,515 as of September 30, 2025.
Collaboration updates include a Clinical Trial Collaboration and Supply Agreement with Pfizer under which Pfizer will supply elranatamab at no cost for a planned Phase 1b multiple myeloma study; C4T will sponsor and fund the trial, and the parties will jointly own clinical data. Merck provided notice to terminate the DAC collaboration effective late November 2025; the $10.0 million upfront tied to that program has been fully recognized. C4T also recorded a $2.0 million Biogen milestone in September and previously added $4.0 million in Roche milestones in March.
C4 Therapeutics, Inc. furnished a press release announcing its financial results and business highlights for the quarter ended September 30, 2025.
The press release, dated November 6, 2025, is included as Exhibit 99.1 to this Form 8-K and is treated as furnished rather than filed under the Exchange Act.
C4 Therapeutics (CCCC) reported an insider equity change by its Chief Scientific Officer. On 10/28/2025, 19,200 shares of Common Stock were acquired at $0.00 upon vesting of previously disclosed RSUs. To cover taxes, the issuer withheld 5,644 shares at $2.58, which the filing states does not represent a sale by the reporting person. Following these transactions, the officer directly beneficially owned 99,356 shares.
C4 Therapeutics announced an underwritten equity offering consisting of 21,895,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 28,713,500 shares. Each share or pre-funded warrant was sold together with accompanying Class A and Class B warrants, at a combined price of $2.47 per share package and $2.4699 per pre-funded package. The company expects approximately $117.0 million in net proceeds, extending its cash runway to the end of 2028. If all warrants are cash exercised in full, aggregate net proceeds are expected to be $341.7 million. Closing is expected on October 17, 2025, subject to customary conditions.
The pre-funded warrants have a $0.0001 exercise price and do not expire. Class A and Class B warrants each have an initial exercise price of $2.22 per share and are exercisable immediately. Class A warrants expire on the earlier of 30 days after public release of nine-month median follow-up data from any expansion cohort in the planned Phase 1b study of cemsidomide with elranatamab or the fifth anniversary; Class B warrants expire on the fifth anniversary and may be mandatorily exercised after six months if the stock closes above $6.66 for ten consecutive trading days. Warrant exercises are subject to a Beneficial Ownership Limitation of 4.99% or 9.99%, adjustable up to 19.99% with 61 days’ notice.